Role of combined procalcitonin and lipopolysaccharide-binding protein as prognostic markers of mortality in patients with ventilator-associated pneumonia.

Cleopas Martin R., Dinajani Mahdi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

to investigate the role of combined Lipopolysaccharide-Binding Protein (LBP) and Procalcitonin (PCT) ) as prognostic marker of mortality in patients with Ventilator-Associated Pneumonia (VAP). this prospective cohort study was held in ICU/HCU of Cipto Mangunkusumo hospital between 2006 to 2007 by taking the subjects consecutively. Thirty five patients with VAP were studied. For analysing the data, chi-square or its alternative Fisher exact test were used. Based on a previous study for evaluation, we used cut off pants of 5 ng/ml and 0.5 ng/ml for PCT and 30 μg/ml and 25 μg/ml for LBP after three-day and seven-day treatment respectively. Receiver operating curve was made to determine the sensitivity and specificity of PCT and LBP as infection markers. 35 patients participated in this study. After three days of therapy, if the level of PCT >5 ng/mL and LBP >30 μg/mL the prognosis would be bad (p<0.05) with a sensitivity of 88.5%, specificity of 53.2% and AUC value 0.69. Poor prognosis was also found if after seven day therapy PCT level was >0.5 ng/mL and LBP level >25 μg/mL (p<0.05) with sensitivity of 96.3%, specificity of 66.7% and AUC value 0.81. examination of combined PCT and LBP can be taken as a good prognostic markers to predict mortality in patients with VAP.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalActa medica Indonesiana
Volume45
Issue number2
Publication statusPublished - 1 Jan 2013

Fingerprint Dive into the research topics of 'Role of combined procalcitonin and lipopolysaccharide-binding protein as prognostic markers of mortality in patients with ventilator-associated pneumonia.'. Together they form a unique fingerprint.

Cite this